Access
This article is part of Nature's premium content.
Published online 4 June 2007 | Nature | doi:10.1038/news070604-1
News
The zero effect
Small quick trials may help shape the development of new drugs.
New clinical-trial results offer not just a modicum of hope for some future cancer patients, but also encouragement for those looking at more efficient techniques for developing new drugs.
Yesterday, scientists from the US National Cancer Institute (NCI) said they had successfully tested a new drug — called ABT-888 — in six patients with various forms of advanced cancer.
To read this story in full you will need to login or make a payment (see right).
Comments
Reader comments are usually moderated after posting. If you find something offensive or inappropriate, you can speed this process by clicking 'Report this comment' (or, if that doesn't work for you, email webadmin@nature.com). For more controversial topics, we reserve the right to moderate before comments are published.
There are currently no comments.
